Literature DB >> 18930950

Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury.

Patrick J Shaw1, Amy C Ditewig, Jeffrey F Waring, Michael J Liguori, Eric A Blomme, Patricia E Ganey, Robert A Roth.   

Abstract

The antibiotic trovafloxacin (TVX) has caused severe idiosyncratic hepatotoxicity in people, whereas levofloxacin (LVX) has not. Mice cotreated with TVX and lipopolysaccharide (LPS), but not with LVX and LPS, develop severe hepatocellular necrosis. Mice were treated with TVX and/or LPS, and hepatic gene expression changes were measured before liver injury using gene array. Hepatic gene expression profiles from mice treated with TVX/LPS clustered differently from those treated with LPS or TVX alone. Several of the probe sets expressed differently in TVX/LPS-treated mice were involved in interferon (IFN) signaling and the janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. A time course of plasma concentrations of IFN-gamma and interleukin (IL)-18, which directly induces IFN-gamma production, revealed that both cytokines were selectively increased in TVX/LPS-treated mice. Both IL-18(-/-) and IFN-gamma(-/-) mice were significantly protected from TVX/LPS-induced liver injury. In addition, IFN-gamma(-/-) mice had decreased plasma concentrations of tumor necrosis factor-alpha, IL-18, and IL-1beta when compared to wild-type mice. In conclusion, the altered expression of genes involved in IFN signaling in TVX/LPS-treated mice led to the finding that IL-18 and IFN-gamma play a critical role in TVX/LPS-induced liver injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930950      PMCID: PMC2638649          DOI: 10.1093/toxsci/kfn205

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  37 in total

1.  A comparison of statistical methods for analysis of high density oligonucleotide array data.

Authors:  Dilip Rajagopalan
Journal:  Bioinformatics       Date:  2003-08-12       Impact factor: 6.937

Review 2.  Phenotypic and functional changes of cytokine-activated neutrophils.

Authors:  Carole Galligan; Teizo Yoshimura
Journal:  Chem Immunol Allergy       Date:  2003

3.  Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?

Authors:  John P Buchweitz; Patricia E Ganey; Steven J Bursian; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

4.  Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

Authors:  George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

5.  Protection against the mortality associated with disease models mediated by TNF and IFN-gamma in mice lacking IFN regulatory factor-1.

Authors:  G Senaldi; C L Shaklee; J Guo; L Martin; T Boone; T W Mak; T R Ulich
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

6.  Endotoxin-induced gamma interferon production: contributing cell types and key regulatory factors.

Authors:  Tushar K Varma; Cheng Y Lin; Tracy E Toliver-Kinsky; Edward R Sherwood
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

Review 7.  Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.

Authors:  V E Anderson; N Osheroff
Journal:  Curr Pharm Des       Date:  2001-03       Impact factor: 3.116

8.  Role of neutrophils in the synergistic liver injury from monocrotaline and bacterial lipopolysaccharide exposure.

Authors:  Steven B Yee; Umesh M Hanumegowda; Jon A Hotchkiss; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2003-03       Impact factor: 4.849

9.  Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2009-04-07       Impact factor: 4.030

10.  Inhibition of interferon-gamma-activated nuclear factor-kappa B by cyclosporin A: A possible mechanism for synergistic induction of apoptosis by interferon-gamma and cyclosporin A in gastric carcinoma cells.

Authors:  Kiichiro Beppu; Takashi Morisaki; Hisashi Matsunaga; Akihiko Uchiyama; Eikichi Ihara; Katsuya Hirano; Hideo Kanaide; Masao Tanaka; Mitsuo Katano
Journal:  Biochem Biophys Res Commun       Date:  2003-06-13       Impact factor: 3.575

View more
  16 in total

Review 1.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

Review 2.  Use of transcriptomics in understanding mechanisms of drug-induced toxicity.

Authors:  Yuxia Cui; Richard S Paules
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

3.  Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related.

Authors:  Kevin M Beggs; Ashley R Maiuri; Aaron M Fullerton; Kyle L Poulsen; Anna B Breier; Patricia E Ganey; Robert A Roth
Journal:  Toxicology       Date:  2015-03-05       Impact factor: 4.221

4.  Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study.

Authors:  Ashley R Maiuri; Bronlyn Wassink; Jonathan D Turkus; Anna B Breier; Theresa Lansdell; Gurpreet Kaur; Sarah L Hession; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2017-07-07       Impact factor: 4.030

5.  Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2008-09-26       Impact factor: 4.030

6.  Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2009-04-07       Impact factor: 4.030

7.  Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity.

Authors:  Patrick J Shaw; Kevin M Beggs; Erica M Sparkenbaugh; Christine M Dugan; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2009-07-28       Impact factor: 4.849

Review 8.  Beyond Metabolism: Role of the Immune System in Hepatic Toxicity.

Authors:  Kenneth L Hastings; Martin D Green; Bin Gao; Patricia E Ganey; Robert A Roth; Gary R Burleson
Journal:  Int J Toxicol       Date:  2020 Mar/Apr       Impact factor: 2.032

9.  Calcium Contributes to the Cytotoxic Interaction Between Diclofenac and Cytokines.

Authors:  Ashley R Maiuri; Anna B Breier; Jonathan D Turkus; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2015-11-24       Impact factor: 4.849

Review 10.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.